Adjunctive Therapy With Inhaled Levodopa Demonstrates Safety in Parkinson Disease

Adjunctive Therapy With Inhaled Levodopa Demonstrates Safety in Parkinson Disease
Combined single inhaled doses of CVT-301 (inhaled levodopa) and oral carbidopa/levodopa therapy taken during early morning OFF symptoms demonstrated tolerability and lack of serious adverse events according to research published in Parkinsonism & Related Disorders. This randomized, double-blinded, 2-way crossover study included 36 individuals (mean age, 62.9 years) with Parkinson disease who self-administered either CVT-301 (84 mg) or placebo during ... read more
Source: Neurology AdvisorPublished on 2019-05-17By jennifermannheim